We found lower levels of TGF-β1 mRNA in the PBMCs of patients six-months-post-MI compared to the controls free of cardiovascular disease, while the difference in TGF-β1 mRNA expression between patients with and without adverse LV remodeling was not statistically significant. The gene discussed is TGFB1; the disease is myocardial infarction.